E7050 + cisplatin + capecitabine
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
Trial Timeline
Nov 1, 2011 → Jul 1, 2013
NCT ID
NCT01355302About E7050 + cisplatin + capecitabine
E7050 + cisplatin + capecitabine is a phase 1/2 stage product being developed by Eisai for Advanced or Metastatic Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT01355302. Target conditions include Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01355302 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors